Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is temsirolimus more safe and effective than interferon α for the treatment of advanced renal cell carcinoma?

Nature Clinical Practice Urology volume 4, pages 586–587 (2007)Cite this article

boxed-textHudes G et al. (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271–2281

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Dutcher JP et al. (2007) Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN). J Clin Oncol 25 (Suppl): 5033

    Google Scholar 

  2. Motzer RJ et al. (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17: 2530–2540

    Article  CAS  Google Scholar 

  3. Motzer RJ et al. (2000) Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 18: 1928–1935

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Rachel Murphy, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. A-R Golshayan is a Fellow in the Department of Hematology and Medical Oncology, and RM Bukowski is a Professor of Medicine and the Director of Experimental Therapeutics at the Cleveland Clinic Taussig Cancer Center, The Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.,

    Ali-Reza Golshayan & Ronald M Bukowski

Authors
  1. Ali-Reza Golshayan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ronald M Bukowski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ronald M Bukowski.

Ethics declarations

Competing interests

Ronald M Bukowski is a consultant for, is on a speakers' bureau for, and has received grant/research support from Bayer, Genentech, Pfizer and Wyeth. He is also a consultant for Novartis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Golshayan, AR., Bukowski, R. Is temsirolimus more safe and effective than interferon α for the treatment of advanced renal cell carcinoma?. Nat Rev Urol 4, 586–587 (2007). https://doi.org/10.1038/ncpuro0915

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpuro0915

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing